UPDATE: Aegis Capital Initiates Coverage on China Biologic Products with Buy Rating, $20 PT

In a report published Wednesday, Aegis Capital Corp. initiated coverage on China Biologic Products (NASDAQ: CBPO ) with a Buy rating and $20.00 price target. Aegis Capital noted, “We are initiating coverage on China Biologic Products (CBPO/NASDAQ) with a Buy rating and a 12-month price target of $20.00 per share.